.Attribute Medication, Posted online: 03 September 2024 doi:10.1038/ s41591-024-03223-zThis Point of view asks for introduction of patients with MASLD and also dimension of liver results in cardio-- kidney-- metabolic tests, when data advise mechanistically possible advantages and scientific security-- and also summarizes factors to consider for trial style and regulative approval.